Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

“By leveraging this agreement, we can offer the Stelara biosimilar at a breakthrough price and can minimize patient disruption through Lumicera’s superior transition support model.” Lumicera delivers ...

Objectives: Biosimilars offer a promising solution to challenges related to healthcare budget sustainability. However, limited patient awareness and understanding often hinder their timely adoption.

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

A quote card featuring Quimbo’s photo and the logo of her official Facebook page, “Teacher Stella Quimbo,” has circulated across social media platforms. It has also been shared by multiple ...

JENNINGS, La. (KLFY) — A Jennings doctor accused of assaulting one of his patients has pleaded not guilty in district court. Bahmen “Ben” Sabbaghian is charged in the 31st Judicial District ...

This milestone underscores our commitment to providing cost-effective, high-quality biosimilars to patients with chronic conditions like psoriasis, expanding access to critical treatments globally,” ...